Advancements in the battle against severe acute respiratory syndrome.
Identifieur interne : 002E46 ( PubMed/Checkpoint ); précédent : 002E45; suivant : 002E47Advancements in the battle against severe acute respiratory syndrome.
Auteurs : David S C. Hui [Hong Kong] ; Gary W K. WongSource :
- Expert opinion on pharmacotherapy [ 1744-7666 ] ; 2004.
Descripteurs français
- KwdFr :
- Anticorps monoclonaux (usage thérapeutique), Antiviraux (usage thérapeutique), Hormones corticosurrénaliennes (usage thérapeutique), Humains, Inhibiteurs de protéases (usage thérapeutique), Interférons (usage thérapeutique), Lopinavir, Pyrimidinones (usage thérapeutique), Ribavirine (usage thérapeutique), Ritonavir (usage thérapeutique), Syndrome respiratoire aigu sévère (), Syndrome respiratoire aigu sévère (physiopathologie), Syndrome respiratoire aigu sévère (épidémiologie), Vaccins antiviraux, Virus du SRAS (immunologie).
- MESH :
- immunologie : Virus du SRAS.
- physiopathologie : Syndrome respiratoire aigu sévère.
- usage thérapeutique : Anticorps monoclonaux, Antiviraux, Hormones corticosurrénaliennes, Inhibiteurs de protéases, Interférons, Pyrimidinones, Ribavirine, Ritonavir.
- épidémiologie : Syndrome respiratoire aigu sévère.
- Humains, Lopinavir, Syndrome respiratoire aigu sévère, Vaccins antiviraux.
English descriptors
- KwdEn :
- Adrenal Cortex Hormones (therapeutic use), Antibodies, Monoclonal (therapeutic use), Antiviral Agents (therapeutic use), Humans, Interferons (therapeutic use), Lopinavir, Protease Inhibitors (therapeutic use), Pyrimidinones (therapeutic use), Ribavirin (therapeutic use), Ritonavir (therapeutic use), SARS Virus (immunology), Severe Acute Respiratory Syndrome (epidemiology), Severe Acute Respiratory Syndrome (physiopathology), Severe Acute Respiratory Syndrome (therapy), Viral Vaccines.
- MESH :
- chemical , therapeutic use : Adrenal Cortex Hormones, Antibodies, Monoclonal, Antiviral Agents, Interferons, Protease Inhibitors, Pyrimidinones, Ribavirin, Ritonavir.
- epidemiology : Severe Acute Respiratory Syndrome.
- immunology : SARS Virus.
- physiopathology : Severe Acute Respiratory Syndrome.
- therapy : Severe Acute Respiratory Syndrome.
- Humans, Lopinavir, Viral Vaccines.
Abstract
Severe acute respiratory syndrome (SARS) is a newly emerged infectious disease with a significant morbidity and mortality. The major clinical features include persistent fever, chills/rigor, myalgia, malaise, dry cough, headache and dyspnoea. Respiratory failure is the major complication of SARS and approximately 20% of patients may progress to acute respiratory distress syndrome requiring invasive mechanical ventilatory support. However, the severity is much milder in infected young children. Treatment of SARS was empirical in 2003 due to our limited understanding of this new disease. Protease inhibitors (lopinavir/ritonavir) in combination with ribavirin may play a role as antiviral therapy in the early phase, whereas the role of IFN and systemic steroid in preventing immune-mediated lung injury deserves further investigation. Knowledge of the genomic sequence of the SARS coronavirus has facilitated the development of rapid diagnostic tests. In addition, other antiviral treatment, RNA interference, monoclonal antibody, synthetic peptides, and vaccines are being developed. This paper provides a review of the epidemiology, clinical features and possible treatment strategies of SARS.
DOI: 10.1517/14656566.5.8.1687
PubMed: 15264983
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:15264983Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Advancements in the battle against severe acute respiratory syndrome.</title><author><name sortKey="Hui, David S C" sort="Hui, David S C" uniqKey="Hui D" first="David S C" last="Hui">David S C. Hui</name><affiliation wicri:level="4"><nlm:affiliation>Department of Pediatrics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong.</nlm:affiliation><country xml:lang="fr">Hong Kong</country><wicri:regionArea>Department of Pediatrics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories</wicri:regionArea><orgName type="university">Université chinoise de Hong Kong</orgName><placeName><settlement type="city">Sha Tin</settlement></placeName></affiliation></author><author><name sortKey="Wong, Gary W K" sort="Wong, Gary W K" uniqKey="Wong G" first="Gary W K" last="Wong">Gary W K. Wong</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2004">2004</date><idno type="RBID">pubmed:15264983</idno><idno type="pmid">15264983</idno><idno type="doi">10.1517/14656566.5.8.1687</idno><idno type="wicri:Area/PubMed/Corpus">002C53</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002C53</idno><idno type="wicri:Area/PubMed/Curation">002C53</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002C53</idno><idno type="wicri:Area/PubMed/Checkpoint">002E46</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002E46</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Advancements in the battle against severe acute respiratory syndrome.</title><author><name sortKey="Hui, David S C" sort="Hui, David S C" uniqKey="Hui D" first="David S C" last="Hui">David S C. Hui</name><affiliation wicri:level="4"><nlm:affiliation>Department of Pediatrics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong.</nlm:affiliation><country xml:lang="fr">Hong Kong</country><wicri:regionArea>Department of Pediatrics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories</wicri:regionArea><orgName type="university">Université chinoise de Hong Kong</orgName><placeName><settlement type="city">Sha Tin</settlement></placeName></affiliation></author><author><name sortKey="Wong, Gary W K" sort="Wong, Gary W K" uniqKey="Wong G" first="Gary W K" last="Wong">Gary W K. Wong</name></author></analytic><series><title level="j">Expert opinion on pharmacotherapy</title><idno type="eISSN">1744-7666</idno><imprint><date when="2004" type="published">2004</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adrenal Cortex Hormones (therapeutic use)</term><term>Antibodies, Monoclonal (therapeutic use)</term><term>Antiviral Agents (therapeutic use)</term><term>Humans</term><term>Interferons (therapeutic use)</term><term>Lopinavir</term><term>Protease Inhibitors (therapeutic use)</term><term>Pyrimidinones (therapeutic use)</term><term>Ribavirin (therapeutic use)</term><term>Ritonavir (therapeutic use)</term><term>SARS Virus (immunology)</term><term>Severe Acute Respiratory Syndrome (epidemiology)</term><term>Severe Acute Respiratory Syndrome (physiopathology)</term><term>Severe Acute Respiratory Syndrome (therapy)</term><term>Viral Vaccines</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Anticorps monoclonaux (usage thérapeutique)</term><term>Antiviraux (usage thérapeutique)</term><term>Hormones corticosurrénaliennes (usage thérapeutique)</term><term>Humains</term><term>Inhibiteurs de protéases (usage thérapeutique)</term><term>Interférons (usage thérapeutique)</term><term>Lopinavir</term><term>Pyrimidinones (usage thérapeutique)</term><term>Ribavirine (usage thérapeutique)</term><term>Ritonavir (usage thérapeutique)</term><term>Syndrome respiratoire aigu sévère ()</term><term>Syndrome respiratoire aigu sévère (physiopathologie)</term><term>Syndrome respiratoire aigu sévère (épidémiologie)</term><term>Vaccins antiviraux</term><term>Virus du SRAS (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Adrenal Cortex Hormones</term><term>Antibodies, Monoclonal</term><term>Antiviral Agents</term><term>Interferons</term><term>Protease Inhibitors</term><term>Pyrimidinones</term><term>Ribavirin</term><term>Ritonavir</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="physiopathologie" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anticorps monoclonaux</term><term>Antiviraux</term><term>Hormones corticosurrénaliennes</term><term>Inhibiteurs de protéases</term><term>Interférons</term><term>Pyrimidinones</term><term>Ribavirine</term><term>Ritonavir</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Lopinavir</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Humains</term><term>Lopinavir</term><term>Syndrome respiratoire aigu sévère</term><term>Vaccins antiviraux</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Severe acute respiratory syndrome (SARS) is a newly emerged infectious disease with a significant morbidity and mortality. The major clinical features include persistent fever, chills/rigor, myalgia, malaise, dry cough, headache and dyspnoea. Respiratory failure is the major complication of SARS and approximately 20% of patients may progress to acute respiratory distress syndrome requiring invasive mechanical ventilatory support. However, the severity is much milder in infected young children. Treatment of SARS was empirical in 2003 due to our limited understanding of this new disease. Protease inhibitors (lopinavir/ritonavir) in combination with ribavirin may play a role as antiviral therapy in the early phase, whereas the role of IFN and systemic steroid in preventing immune-mediated lung injury deserves further investigation. Knowledge of the genomic sequence of the SARS coronavirus has facilitated the development of rapid diagnostic tests. In addition, other antiviral treatment, RNA interference, monoclonal antibody, synthetic peptides, and vaccines are being developed. This paper provides a review of the epidemiology, clinical features and possible treatment strategies of SARS.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15264983</PMID><DateCompleted><Year>2005</Year><Month>06</Month><Day>27</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1744-7666</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>8</Issue><PubDate><Year>2004</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Expert opinion on pharmacotherapy</Title><ISOAbbreviation>Expert Opin Pharmacother</ISOAbbreviation></Journal><ArticleTitle>Advancements in the battle against severe acute respiratory syndrome.</ArticleTitle><Pagination><MedlinePgn>1687-93</MedlinePgn></Pagination><Abstract><AbstractText>Severe acute respiratory syndrome (SARS) is a newly emerged infectious disease with a significant morbidity and mortality. The major clinical features include persistent fever, chills/rigor, myalgia, malaise, dry cough, headache and dyspnoea. Respiratory failure is the major complication of SARS and approximately 20% of patients may progress to acute respiratory distress syndrome requiring invasive mechanical ventilatory support. However, the severity is much milder in infected young children. Treatment of SARS was empirical in 2003 due to our limited understanding of this new disease. Protease inhibitors (lopinavir/ritonavir) in combination with ribavirin may play a role as antiviral therapy in the early phase, whereas the role of IFN and systemic steroid in preventing immune-mediated lung injury deserves further investigation. Knowledge of the genomic sequence of the SARS coronavirus has facilitated the development of rapid diagnostic tests. In addition, other antiviral treatment, RNA interference, monoclonal antibody, synthetic peptides, and vaccines are being developed. This paper provides a review of the epidemiology, clinical features and possible treatment strategies of SARS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hui</LastName><ForeName>David S C</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Gary W K</ForeName><Initials>GW</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Opin Pharmacother</MedlineTA><NlmUniqueID>100897346</NlmUniqueID><ISSNLinking>1465-6566</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000305">Adrenal Cortex Hormones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011480">Protease Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011744">Pyrimidinones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>2494G1JF75</RegistryNumber><NameOfSubstance UI="D061466">Lopinavir</NameOfSubstance></Chemical><Chemical><RegistryNumber>49717AWG6K</RegistryNumber><NameOfSubstance UI="D012254">Ribavirin</NameOfSubstance></Chemical><Chemical><RegistryNumber>9008-11-1</RegistryNumber><NameOfSubstance UI="D007372">Interferons</NameOfSubstance></Chemical><Chemical><RegistryNumber>O3J8G9O825</RegistryNumber><NameOfSubstance UI="D019438">Ritonavir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000305" MajorTopicYN="N">Adrenal Cortex Hormones</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007372" MajorTopicYN="N">Interferons</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061466" MajorTopicYN="N">Lopinavir</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011480" MajorTopicYN="N">Protease Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011744" MajorTopicYN="N">Pyrimidinones</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012254" MajorTopicYN="N">Ribavirin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019438" MajorTopicYN="N">Ritonavir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>77</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>7</Month><Day>22</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>6</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>7</Month><Day>22</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15264983</ArticleId><ArticleId IdType="pii">EOP050802</ArticleId><ArticleId IdType="doi">10.1517/14656566.5.8.1687</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Hong Kong</li></country><settlement><li>Sha Tin</li></settlement><orgName><li>Université chinoise de Hong Kong</li></orgName></list><tree><noCountry><name sortKey="Wong, Gary W K" sort="Wong, Gary W K" uniqKey="Wong G" first="Gary W K" last="Wong">Gary W K. Wong</name></noCountry><country name="Hong Kong"><noRegion><name sortKey="Hui, David S C" sort="Hui, David S C" uniqKey="Hui D" first="David S C" last="Hui">David S C. Hui</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002E46 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 002E46 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:15264983
|texte= Advancements in the battle against severe acute respiratory syndrome.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:15264983" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |